BR112022025861A2 - Gel vaginal - Google Patents

Gel vaginal

Info

Publication number
BR112022025861A2
BR112022025861A2 BR112022025861A BR112022025861A BR112022025861A2 BR 112022025861 A2 BR112022025861 A2 BR 112022025861A2 BR 112022025861 A BR112022025861 A BR 112022025861A BR 112022025861 A BR112022025861 A BR 112022025861A BR 112022025861 A2 BR112022025861 A2 BR 112022025861A2
Authority
BR
Brazil
Prior art keywords
gel
vaginal gel
vaginal
composition
terconazole
Prior art date
Application number
BR112022025861A
Other languages
English (en)
Inventor
J Borgman Robert
E Juul James
Original Assignee
Nat Medical Supply Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Medical Supply Llc filed Critical Nat Medical Supply Llc
Publication of BR112022025861A2 publication Critical patent/BR112022025861A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

GEL VAGINAL. A presente invenção refere-se a uma composição com consistência similar a gel que contém metronidazol, terconazol, um espessante fisiologicamente aceitável e água. A composição é útil para o tratamento de vaginose bacteriana, bem como de candidíase vulvovaginal.
BR112022025861A 2020-06-18 2021-04-22 Gel vaginal BR112022025861A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/904,678 US11529346B2 (en) 2020-06-18 2020-06-18 Vaginal gel
PCT/US2021/028631 WO2021257179A1 (en) 2020-06-18 2021-04-22 Vaginal gel

Publications (1)

Publication Number Publication Date
BR112022025861A2 true BR112022025861A2 (pt) 2023-03-14

Family

ID=79022797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025861A BR112022025861A2 (pt) 2020-06-18 2021-04-22 Gel vaginal

Country Status (14)

Country Link
US (1) US11529346B2 (pt)
EP (1) EP4167964A1 (pt)
JP (1) JP2023531443A (pt)
KR (1) KR20230026456A (pt)
CN (1) CN115955967A (pt)
AR (1) AR122687A1 (pt)
AU (1) AU2021292945A1 (pt)
BR (1) BR112022025861A2 (pt)
CA (1) CA3182553A1 (pt)
CO (1) CO2023000415A2 (pt)
IL (1) IL299066A (pt)
MX (1) MX2022016348A (pt)
TW (1) TW202214247A (pt)
WO (1) WO2021257179A1 (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
FR2777783A1 (fr) 1998-04-24 1999-10-29 Innothera Lab Sa Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses
US20030130225A1 (en) * 2001-10-16 2003-07-10 Nawaz Ahmad Novel methods of treating local fungal and bacterial infections
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
MXPA05004578A (es) * 2002-10-31 2005-07-26 Umd Inc Composicion terapeutica para el suministro de drogas a y a traves de epitelios de proteccion.
US6913759B2 (en) * 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
GB0405406D0 (en) * 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US10398692B2 (en) 2006-09-12 2019-09-03 Curatek Pharmaceuticals Holding, Inc. Terconazole composition and method
CN103536592B (zh) * 2013-10-11 2015-04-08 哈尔滨欧替药业有限公司 甲硝唑呋喃唑酮阴道膨胀栓及其制备方法和检测方法
ITRM20130690A1 (it) * 2013-12-17 2015-06-18 Over S R L Composizioni per il trattamento topico delle infezioni da gardnerella vaginalis
EP3388063A1 (en) * 2017-04-14 2018-10-17 Adamed sp. z o.o. Treatment of a bacterial vaginal infection

Also Published As

Publication number Publication date
KR20230026456A (ko) 2023-02-24
IL299066A (en) 2023-02-01
TW202214247A (zh) 2022-04-16
CA3182553A1 (en) 2021-12-23
CN115955967A (zh) 2023-04-11
MX2022016348A (es) 2023-03-06
AU2021292945A1 (en) 2023-02-16
EP4167964A1 (en) 2023-04-26
WO2021257179A1 (en) 2021-12-23
US20210393619A1 (en) 2021-12-23
JP2023531443A (ja) 2023-07-24
US11529346B2 (en) 2022-12-20
AR122687A1 (es) 2022-09-28
CO2023000415A2 (es) 2023-01-26

Similar Documents

Publication Publication Date Title
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
CL2017000998A1 (es) Composición que comprende un agente de control biológico de la especie bacillus subtilis y un fungicida del grupo de inhibidores de la mitosis y la división celular, tal como fenamidona. (divisional solicitud 3272-2014)
HN2011001759A (es) Regimen de dosificacion para un agonista de los receptores de s1p
UY32350A (es) Régimen de dosificación de un agonista de los receptores de s1p
PA8841901A1 (es) Compuestos orgánicos
CR11723A (es) Agente para tratar enfermedad
ECSP077989A (es) Formulación de diclofenac y métodos para usarlas
BR112012009891A2 (pt) métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
PE20142367A1 (es) Formulaciones de imiquimod
SV2013004451A (es) Compuestos y su uso
BR112013033759A8 (pt) Forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol
CL2019002220A1 (es) Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos.
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
CO2022000481A2 (es) Inhibidores de enzimas
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
FR3064473B1 (fr) Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale
CO2022014673A2 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii
NZ709209A (en) Internal ultrasound gel
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
BR112022025861A2 (pt) Gel vaginal
CO6321268A2 (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
PH12019502332A1 (en) Treatment of a bacterial vaginal infection